Innate Pharma/IPHA

$2.44

3.82%
-
1D1W1MYTD1YMAX

About Innate Pharma

Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Ticker

IPHA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Herve Brailly

Employees

179

Headquarters

Marseille, France

Innate Pharma Metrics

BasicAdvanced
$185.43M
Market cap
-
P/E ratio
-$0.10
EPS
0.31
Beta
-
Dividend rate
$185.43M
0.31382
$3.57
$1.81
10.38K
3.734
146.408
178.359
-3.86%
-14.28%
-4.87%
3.348
3.518
3.375
4.68%
87.13%
-2.59%

What the Analysts think about Innate Pharma

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
201.23% upside
High $11.41
Low $2.49
$2.44
Current price
$7.35
Average price target

Innate Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-55.75% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€16.5M
-53.26%
Net income
€-9.2M
-641.18%
Profit margin
-55.75%
-1,259.04%

Innate Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 65.63%
QuarterlyAnnual
Q2 22
Q4 22
Q2 23
Q4 23
Q2 24
Actual
€0.08
-€0.29
€0.02
-€0.11
-
Expected
-€0.15
-€0.39
-€0.14
-€0.32
-€0.32
Surprise
-154.55%
-25.64%
-114.29%
-65.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Innate Pharma stock?

Innate Pharma (IPHA) has a market cap of $185.52M as of April 21, 2024.

What is the P/E ratio for Innate Pharma stock?

The price to earnings (P/E) ratio for Innate Pharma (IPHA) stock is 0 as of April 21, 2024.

Does Innate Pharma stock pay dividends?

No, Innate Pharma (IPHA) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Innate Pharma dividend payment date?

Innate Pharma (IPHA) stock does not pay dividends to its shareholders.

What is the beta indicator for Innate Pharma?

Innate Pharma (IPHA) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Innate Pharma stock price target?

The target price for Innate Pharma (IPHA) stock is $7.39, which is 202.87% above the current price of $2.44. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Innate Pharma stock

Buy or sell Innate Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing